2022
29 April 2022 – Bonus Options Issue – Letter to Shareholders
28 April 2022 – ANP Quarterly Update & Appendix 4C
14 April 2022 – Receipt of R&D Tax Incentive payment
12 April 2022 – ANP – Prospectus – Options
12 April 2022 – Bonus Option Offer
14 March 2022 – Significant modulation of two bone morphogenetic proteins supports potential of ATL1102 for improving bone density in DMD
1 March 2022 – Poster Presentation at 2022 MDA Clinical & Scientific Conference
24 February 2022 – Long COVID-19 strategic collaboration with US Experts
23 February 2022 – Half Yearly Report and Accounts
8 February 2022 – ATL1102 MCRI Collaboration Dosing Commenced
27 January 2022 – Quarterly Update and Apendix 4C
2021
22 December 2022 – Change of Director’s Interest Notice (MD)
22 December 2021 – Entitlement Offer results
15 December 2021 – Results of Annual General Meeting
15 December 2021 – ANP – AGM Presentation
14 December – 2021 – Positive PIP Decision from UK MHRA & ratification of PDCO opinion by EMA
9 December 2021 – ATL1102 Toxicology Protocol submitted to US FDA
23 November 2021 – Entitlement Offer extension
15 November 2021 – Notice of Meeting & Proxy Form
5 November 2021 – Prospectus
5 November 2021 – Application for Quotation of Securities – Appendix 2A
5 November 2021 – Placement & Cleansing Notice
1 November 2021 – Investor Presentation 1 Nov 2021
1 November 2021 – Appendix 3B
1 November 2021 – Positive PDCO Opinion & $20M Placement
29 October 2021 – 2021 Annual Report
29 October 2021 – Appendix 4G & Governance Statement 2021
29 October 2021 – Quarterly Update and Apendix 4C
4 October 2021 – Antisense Therapeutics appoints new Non-Executive Director
30 September 2021 – Positive feedback received on Paediatric Investigation Plan
24 September 2021 – Statistically significant modulation in two DMD disease modifier proteins supports potential of ATL1102 in ambulant DMD and fibrotic conditions
20 September 2021 – New ATL1102 proteomics data to be presented in a Late Breaking News Abstract at the World Muscle Society 2021 Virtual Congress
25 August 2021 – Appendix 4E – Audited Financial Report Year Ended 30 June 2021
24 August 2021 – ANP to participate in PPMD development of new Community-Led Duchenne Guidance for FDA
12 August 2021 – ANP Updates on US Regulatory Plans for ATL1102 in DMD
28 July 2021 –Antisense Therapeutics transitions to new Board Chair
22 June 2021 – ATL1102 for DMD EMA PIP feedback and FDA regulatory progress
1 June 2021 – US FDA Feedback on Type C Meeting for ATL1102 in the US
26 May 2021 – Manufacture of ATL1102 clinical supplies for Phase IIb trial in DMD
28 April 2021 – Quarterly Report & Appendix 4C_March 2021
23 April 2021 – ATL1102 FDA Type C meeting
24 March 2021 – Director’s Initial Interest Notice
22 March 2021 – Appointment of new Non-Executive Director
19 March 2021 – Appendix 3G
4 March 2021 – FDA Rare Disease Day
26 February 2021 – Jett Foundation Rare Disease Day
25 February 2021 – Paediatric Investigation Plan for ATL1102 in DMD submitted to European Medicines Agency
24 February 2021 – Appointment of Joint Company Secretary
24 February 2021 – Half Yearly Report and Half Year Accounts
15 February 2021 – Antisense Therapeutics granted Type C meeting with US FDA for ATL1102 in DMD
28 January 2021 – Appendix 4C & Quarterly Report_31 Dec 20 QTR_Final